AOD-9604 for Fat Loss: What the Research Actually Found

AOD-9604 has a more serious background than most fat-loss peptides you’ll read about online. It came from a real drug company, went through real human trials, and then quietly failed at the final stage. Here’s what actually happened, based on the trial data, not the marketing.

What Is AOD-9604?

AOD-9604 is a lab-made peptide built from a small piece of human growth hormone. It was created in the 1990s by researchers at Monash University in Australia, working with a company called Metabolic Pharmaceuticals.

The goal was simple. Growth hormone burns fat, but it also raises blood sugar, spikes IGF-1, and can cause unwanted tissue growth. Scientists wanted to isolate just the fat-burning part of the hormone, without those side effects.

How It’s Supposed to Work?

In lab studies, AOD-9604 did two things to fat cells. It sped up the breakdown of stored fat, and it slowed down the creation of new fat. It did this without raising blood sugar or IGF-1, which made it look promising on paper.

In obese mice, it reduced body weight compared to untreated animals. That result disappeared in mice missing a specific fat-related receptor, which told researchers the effect worked through one particular pathway, not a broad, generic mechanism.

What Happened in Human Trials

This is the part most websites skip.

The company ran a full trial program: Phase I, Phase II, and a larger Phase IIb trial with around 300 obese adults. Nearly 900 people took part across all the studies, and the safety results were clean. No major red flags.

But the final, most important trial told a different story. In 2007, the Phase IIb results showed no statistically meaningful weight loss compared to placebo. Whatever small effect had shown up earlier wasn’t strong enough to matter. The company stopped development, and no larger trial ever followed.

It was safe. It just didn’t work well enough in humans.

Why It Worked in Mice but Not People

This gap is common in drug research, not unique to AOD-9604.

Obese mice, especially lab-bred strains, often respond to compounds in ways that don’t carry over to human biology. A peptide can look great in animal testing and still fail a real, controlled human trial. That’s exactly what happened here.

Is AOD-9604 Approved Anywhere?

No. As of 2026, no major health authority, not the FDA, not the European Medicines Agency, not Australia’s TGA, has approved AOD-9604 as a treatment for anything.

Australia did approve it as a food ingredient back in 2012, but that’s a food classification, not drug approval, and it says nothing about whether it actually helps with fat loss.

In the US, the FDA reviewed AOD-9604 in December 2024 for use in compounding pharmacies and turned it down, citing limited long-term safety data. It’s also banned for competitive athletes by the World Anti-Doping Agency. Today, it’s sold only as a research chemical, not a medicine.

What’s Actually Proven vs. What Isn’t

What the research supports:

• The fat-loss mechanism is real and was shown in lab and animal studies
• The human safety data from the trial program was clean
• The final human trial failed to show meaningful weight loss

What isn’t supported:

• No health authority has approved it for any use
• Any claim of significant fat loss in humans goes beyond what the actual trial showed
• There’s little safety data outside that original trial program

Conclusion

AOD-9604 is a case of good science that didn’t pan out. The idea behind it was sound, the safety record was clean, but the human trial that mattered most didn’t show real weight loss. It remains unapproved everywhere, banned in sport, and sold only as a research chemical. If you see strong fat-loss claims about it, the actual trial history says otherwise.